This interview discusses how BCMA-directed CAR T-cell therapy in multiple myeloma may be more effective when administered ...
Nona Biosciences ("Nona"), a global biotechnology company advancing biologics discovery through innovative technology ...
Patients treated in an outpatient setting who later required admission spent an average of 12.1 days in the hospital, ...
MedPage Today on MSN
CAR-like T cells enhance tumor response in gastroesophageal cancer
Liu described the CAR-like T cells as cytokine-activated lymphocytes engineered with the tumor-targeting and -penetrating ...
A next-generation, anti-CD19 enhanced CAR T-cell therapy that secretes interleukin-18 achieved a response in 81% of lymphoma patients who failed previous CAR T-cell therapy. Duration of response was 9 ...
Chimeric antigen receptor natural killer (CAR-NK) cell therapy is emerging as a promising next-generation immunotherapy with ...
Imagine a super-charged immune cell that can launch a focused attack on stubborn solid tumors - a smart fighter that destroys cancer cells for days without tiring. USC biomedical engineers have made ...
Colleen Mabasa, a patient with multiple myeloma, discusses her CAR T-cell therapy journey and the pivotal role self-advocacy ...
Applied Cells Inc. and Immuneel Therapeutics Private Limited today announced that the companies have entered into a collaboration framework to jointly evaluate application of Applied Cells' MARS(R) ...
Nona Biosciences inks agreement with Link Cell Therapies to advance CAR-T cell therapies: Cambridge, Massachusetts Monday, January 12, 2026, 11:00 Hrs [IST] Nona Biosciences (Nona ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback